# Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

> **NCT00116610** · PHASE2 · COMPLETED · sponsor: **Poniard Pharmaceuticals** · enrollment: 75 (—)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** picoplatin

## Key facts

- **NCT ID:** NCT00116610
- **Lead sponsor:** Poniard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-03
- **Final completion:** 2008-03
- **Target enrollment:** 75 (—)
- **Last updated:** 2009-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116610, "Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00116610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*